Mass Spectrometry Kit

Tyrosine Kinases Inhibitors Mass Spectrometry kit

Home

Tyrosine Kinases Inhibitors Mass Spectrometry kit
[13C,2H3]-Pazopanib hydrochloride

Pazopanib-13C-D3 (1261398-44-0)
[2H10]-Sunitinib

Sunitinib-D10 (1126721-82-1)
[2H8]-Dasatinib

Dasatinib-D8 (1132093-70-9)
[13C6]-Erlotinib hydrochloride

Erlotinib-13C6 (1210610-07-3 )
[2H8]-Gefitinib

Gefitinib-D8 (857091-32-8)
[13C,2H3]-Axitinib

Axitinib-13C-D3 (1261432-00-1)
[13C,2H3]-Nilotinib

Nilotinib-13C-D3 (1261398-62-2)
[13C,2H3]-Sorafenib

Sorafenib-13C-D3 (1210608-86-8)
[2H8]-Imatinib

Imatinib-D8 (1092942-82-9)
[13C,2H7]-Lapatinib

Lapatinib-13C-D7 (1210608-87-9)
Tyrosine Kinases Inhibitors Mass Spectrometry kit
The treatment of some cancer patients has shifted from traditional, non-specific cytotoxic chemotherapy to chronic treatment with molecular targeted therapies. Imatinib mesylate, a selective inhibitor of tyrosine kinases (TKIs) is the most prominent example of this new era and has opened the way to the development of several additional TKIs, including sunitinib, erlotinib hydrochloride, nilotinib, dasatinib, sorafenib and lapatinib, in the treatment of various hematological malignancies and solid tumors.

Keywords: LC–MS/MS, Anticancer targeted therapy, Tyrosine kinase inhibitors, Erlotinib Hydrochloride , Imatinib, Nilotinib, Dasatinib, Sunitinib, Sorafenib, Lapatinib, Plasma, TKI, Mass Spectrometry Kit, Therapeutic Drug Monitoring, Reagent Kits, Mass Spectrometry Kit, Reagent Kit, Mass Spec kit, Mass Spectrometry Quantification, HPLC-MS method validation, LC-MS-MS method validation, Deuterated internal standard, Routine clinical monitoring, Quantitative bioanalytical methods, Quantification in blood samples, Blood concentrations, Analysis, Clinical diagnostic, Drug Dosing, Analytical method development, Internal standard method, Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry, Standardize blood quantification, Mass Spectrometry Assay Kit, Method for routine quantification.

If you find that a product is not part of our current offering,
we strongly encourage you to place a request for a quotation nonetheless.




® Unless otherwise stated, all texts and images are protected by copyright © 2014-2015 Alsachim,
contact@alsachim.com Terms of Use : Alsachim web site is best viewed on a preferred
screen size of 1024 x 768 pixel resolution or higher. -> Site map